George  Demetri net worth and biography

George Demetri Biography and Net Worth

Director of Blueprint Medicines
George D. Demetri, M.D., FASCO has served as a member of our board of directors since December 2014. Since 1989, Dr. Demetri has served on the faculty of the Dana-Farber Cancer Institute, or Dana-Farber, and Harvard Medical School, where he is a Professor of Medicine and serves as one of the Directors of the Ludwig Center at Harvard. At Dana-Faber, Dr. Demetri is the Senior Vice President for Experimental Therapeutics, as well as an Associate Director for Clinical Sciences at the NCI-designated Dana-Farber/Harvard Comprehensive Cancer Center Consortium. Dr. Demetri’s research and clinical interests have centered on mechanism-based drug development for solid tumors, with an emphasis on molecularly defined subsets of sarcomas such as gastrointestinal stromal tumors. Dr. Demetri has contributed to the development of several new drugs for sarcomas and other malignancies, including imatinib, sunitinib, dasatinib, trabectedin, everolimus, pazopanib and regorafenib. He was also a member of the scientific advisory board for Plexxikon Inc. and helped to develop the mutant BRAF inhibitor, vemurafenib. In addition, Dr. Demetri has served as a member of the board of directors of Merrimack Pharmaceuticals, Inc. since December 2017. Dr. Demetri serves as chair of the Science Policy and Government Affairs Committee for the American Association for Cancer Research as well as several other scientific and editorial advisory boards. Dr. Demetri received an A.B. in biochemistry from Harvard College and an M.D. from Stanford University School of Medicine. We believe that Dr. Demetri’s more than 25 years of experience as an oncologist and his significant leadership experience on various national and international scientific and company advisory boards qualifies him to serve as a member of our board of directors.

What is George Demetri's net worth?

The estimated net worth of George Demetri is at least $548,885.28 as of March 17th, 2022. Dr. Demetri owns 5,812 shares of Blueprint Medicines stock worth more than $548,885 as of March 28th. This net worth approximation does not reflect any other investments that Dr. Demetri may own. Learn More about George Demetri's net worth.

How do I contact George Demetri?

The corporate mailing address for Dr. Demetri and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on George Demetri's contact information.

Has George Demetri been buying or selling shares of Blueprint Medicines?

George Demetri has not been actively trading shares of Blueprint Medicines in the last ninety days. Most recently, George Demetri sold 10 shares of the business's stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $58.56, for a transaction totalling $585.60. Following the completion of the sale, the director now directly owns 5,812 shares of the company's stock, valued at $340,350.72. Learn More on George Demetri's trading history.

Who are Blueprint Medicines' active insiders?

Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (COO), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.

Are insiders buying or selling shares of Blueprint Medicines?

In the last twelve months, insiders at the biotechnology company sold shares 23 times. They sold a total of 167,543 shares worth more than $13,239,414.59. The most recent insider tranaction occured on March, 20th when Director Jeffrey W Albers sold 25,073 shares worth more than $2,188,371.44. Insiders at Blueprint Medicines own 3.9% of the company. Learn More about insider trades at Blueprint Medicines.

Information on this page was last updated on 3/20/2024.

George Demetri Insider Trading History at Blueprint Medicines

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/17/2022Sell10$58.56$585.605,812View SEC Filing Icon  
1/4/2021Sell758$112.15$85,009.703,562View SEC Filing Icon  
9/22/2020Sell1,704$85.00$144,840.004,320View SEC Filing Icon  
1/10/2020Sell568$85.00$48,280.002,462View SEC Filing Icon  
1/7/2020Sell1,705$80.59$137,405.953,030View SEC Filing Icon  
6/17/2019Sell1,136$98.50$111,896.005,303View SEC Filing Icon  
3/19/2018Sell5,492$100.09$549,694.2810,231View SEC Filing Icon  
See Full Table

George Demetri Buying and Selling Activity at Blueprint Medicines

This chart shows George Demetri's buying and selling at Blueprint Medicines by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Blueprint Medicines Company Overview

Blueprint Medicines logo
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $94.44
Low: $93.50
High: $95.98

50 Day Range

MA: $86.06
Low: $73.17
High: $99.79

2 Week Range

Now: $94.44
Low: $41.54
High: $101.00

Volume

119,739 shs

Average Volume

802,354 shs

Market Capitalization

$5.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63